Stereoselective Synthesis of Neo-c-glycopeptide Building Blocks: Towards a Flexible and Control-oriented Design as probes for Carbonhydrate-protein Interactions by Arya, Prabhat et al.
NRC Publications Archive (NPArC)
Archives des publications du CNRC (NPArC)
Publisher’s version  /   la version de l'éditeur: 
Bioorganic & Medicinal Chemistry Letter, 7, 12, pp. 1537-1542
Stereoselective Synthesis of Neo-c-glycopeptide Building Blocks: 
Towards a Flexible and Control-oriented Design as probes for 
Carbonhydrate-protein Interactions
Arya, Prabhat; Dion, Sylvain; Shimizu, George K.H.
Contact us / Contactez nous: nparc.cisti@nrc-cnrc.gc.ca.  
http://nparc.cisti-icist.nrc-cnrc.gc.ca/npsi/jsp/nparc_cp.jsp?lang=fr
L’accès à ce site Web et l’utilisation de son contenu sont assujettis aux conditions présentées dans le site
Web page / page Web
http://dx.doi.org/10.1016/S0960-894X(97)00255-2
http://nparc.cisti-icist.nrc-cnrc.gc.ca/npsi/ctrl?action=rtdoc&an=12327875&lang=en
http://nparc.cisti-icist.nrc-cnrc.gc.ca/npsi/ctrl?action=rtdoc&an=12327875&lang=fr
LISEZ CES CONDITIONS ATTENTIVEMENT AVANT D’UTILISER CE SITE WEB.
READ THESE TERMS AND CONDITIONS CAREFULLY BEFORE USING THIS WEBSITE. 
Access and use of this website and the material on it  are subject to the Terms and Conditions set forth at
http://nparc.cisti-icist.nrc-cnrc.gc.ca/npsi/jsp/nparc_cp.jsp?lang=en
Pergamon 
Bioorganic & Medicinal Chemistry Letters, Vol. 7, No. 12. pp. 1537-1542, 1997 
© 1997 Elsevier Science Ltd 
All rights reserved. Printed in Great Britain 
0960-894X/97 $17.00 + 0.00 
PII: S0960-894X(97)00255-2 
STEREOSELECTIVE SYNTHESIS OF NEO-C-GLYCOPEPTIDE BUILDING BLOCKS: 
TOWARDS A FLEXIBLE AND CONTROL-ORIENTED DESIGN AS 
PROBES FOR CARBOHYDRATE-PROTEIN INTERACTIONS 1 
Prabhat Arya,* Sylvain Dion, and George K. H. Shimizu 
Steacie Institute for Molecular Sciences 
National Research Council of Canada, Ottawa, Ontario, Canada, KIA OR6 
Abstract: Neo-C-glycopeptides (1-4) have been synthesized as building blocks to obtain higher neo-C- 
glycopeptides as probes for studying carbohydrate-protein interactions. A convergent approach for the synthesis 
of 4 has been developed, in which two galactose units are attached to a glycine derivative in a stepwise 
procedure (reductive amination followed by amide coupling) and finally coupling to the protected dipeptide 
having a free amino group on the side chain. © 1997 Elsevier Science Ltd. 
Individually weak, noncovalent interactions between protein receptors and carbohydrate ligands form the 
basis of recognition events that are fundamental to a vastly diverse range of intercellular processes. 2 Molecules 
capable of modulating or displacing these interactions offer a plethora of potential applications ranging from 
anti-viral agents, growth regulators to synthetic vaccines. Examples that are currently the focus of numerous 
zealous research efforts include: (i) mimics of Sialyl Lewis X, a cell surface tetrasaccharide that is a ligand for 
the endothelial leucocyte adhesion molecule, E-Selectin; 3 (ii) syntheses of compounds capable of blocking 
influenza virus haemagglutinin binding to cell surface sialic acid residues, the first step in infection of a cell by 
the virus; 4 (iii) the design of oligosaccharide constructs, which inhibit mammalian gamete adhesion in the zona 
pellucida (ZP). 5 It has been postulated that, in mouse ZP, the terminal saccharides involved in this recognition 
are galactose units c~-liuked to the penultimate sugars. 6 
In order to compensate for the weak forces that characterize carbohydrate-protein interactions, 2 both 
Nature, 7 and subsequent attempts by various groups to mimic Nature, 8 have employed multivalency as a tool to 
augment individual ligand-receptor interactions, the so-called "cluster effect". 2c However, equally significant to 
enhancing the binding avidity of carbohydrate mimics is the elucidation of the interactions that dictate the 
specificity of a given recognition event. In certain cases, after synthesis of a series of neoglycoconjugates, 
binding of the saccharide mimics has been used to infer structural details of the protein receptor and to illustrate 
the subtle nature of the complementary interaction. 9 
After several years of efforts in mimicking cell surface carbohydrates, the development of  flexible and 
appropriate designs of  scaffolds to present carbohydrate units in multivalent orientations appears to be an 
important milestone.2c,Sj Towards this goal, we are developing a flexible and control-oriented model for 
multivalent presentations of the terminal saccharides that couples the intrinsic structural variation provided by a 
peptide backbone l0 with the enhanced enzymatic stability offered by C-glycosidic linkages, ll In several cases, 
it has been illustrated that the terminal saccharide represents the minimum recognition motif for the protein 
receptor and that the penultimate sugar's main function is as a scaffolding to properly orient the terminal 
saccharide to maximize the binding interaction. 10a Our strategy is to display the stable mimics of terminal 
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saccharides (i.e., replacement of anomeric oxygen by carbon) as recognition elements on a peptide backbone as 
shown schematically in Figure 1. Optimization in the design of probes for studying carbohydrate-protein 
interactions can be achieved by the variation of spacers 1, 2 and 3, which allows for diversity in the display of 
terminal saccharides. Our approach offers: (i) systematic building block assembly using solid-phase chemistry; 
(ii) highly controlled, yet broad, structural variation; (iii) secondary interactions with adjacent amino acid 
residues, which may further augment binding; and (iv) the incorporation of markers (e.g., biotin) either at the N- 
or C-terminal of the peptide backbone. This model can also exploit the growing library of techniques available 
for glycopeptide synthesis 12 and be applied to the generation of a combinatorial library of stable 
neoglycoconjugates.13 
Figure 1 
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In this communication, we illustrate our approach by reporting the synthesis of four neo-C-glycopeptides 
as building blocks, shown in Figure 2, required for the synthesis of higher neo-C-glycopeptides as probes for 
studying carbohydrate-protein interactions. For the initial studies, we have selected a-galactose as the terminal 
sugar in the neo-C-glycopeptide building blocks (1-4) to demonstrate our control-oriented approach. 
Figure 2 
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The peptide unit of compounds 1-4 was obtained from the dipeptide a-N(Fmoc)-e-N(tBoc)-L-Lys-Gly- 
OBn (Scheme 1, 7), which was prepared from the commercially available ~-N(Fmoc)-e-N(tBoc)-L-Lys-OH (5) 
and the p-toluenesulfonic acid salt of Gly-OBn (6) by a DCC/HOBt coupling method in 92% isolated yield after 
purification over silica gel by flash column chromatography. The fully protected dipeptide (7), on brief exposure 
to trifluoroacetic acid (TFA), gave 8 with the E-side chain amino group as the TFA salt. Compound 8 was 
directly used for coupling with the glycoside units, c~-C-galactose derivatives 11 and 12. 
O a R H N ' ~ " ' ~  H O 
B°oHN_ , ~ ~ . . .  + -OTs ÷H3N.~OBn ~ FmooHN.J~ Nv~OBn 
FmocHN COOH 92% O 
(5) (6) (7) R: Boc 1 b 95% (8) R: H . ~  
Scheme 1: (a) DCC, HOBt, DIEA, CH2C12; (b) TFA, CH2CI 2. 
The ~-C-galactose derivatives (Scheme 2, 11 and 12), were obtained from I~-D-galactose pentaacetate (9) 
through a number of steps. Stereoselective c~-C-allylation of 9 by allyltrimethylsilane and BF3.Et20 as a Lewis 
acid gave 10 in 75% isolated yield after purification. 14a The c~-C-Allyl group of 10 was converted to the 
aldehyde derivative, 11, by ozonolysis (03, CH2C12, -78 °C) followed by the reduction of the ozonide 
(Zn/AcOH, 0 oC). Subsequently, 11 was oxidized to the carboxylic acid derivative 12, via a Masamune 
oxidation. 14b 
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Scheme 2: (a) Allyltrimethylsilane, BF3.Et20, CH2C12, 4 °C; (b) (i) O 3, CH2C12, -78 °C; (ii) Zn/AcOH, 0 °C; (c) 
KMnO4, t-BuOH-5% NaH2PO4. 
With the completion of the synthesis of the peptide and glycoside subunits, the neo-glycopeptide building 
blocks 1-3 (Figure 1) were assembled as shown in Scheme 3. Neo-glycopeptide 1 was synthesized by the 
coupling of dipeptide 8 with glycoside 12 under DCC/HOBt reaction conditions. Purification over silica gel 
gave 1 in 87% isolated yield. 15 Mono-reductive amination of 8 with glycoside 11 gave 13 in 58% isolated yield 
after purification over silica gel. Under similar reaction conditions, but using 2.2 equiv of 11, di-reductive 
amination of 8 was performed to give the neo-glycopeptide 2 in 65% isolated yield after purification.15 Neo- 
glycopeptide 3 was synthesized from 13 in 72% yield after purification by coupling with 12 under DCC/HOBt 
reaction conditions. 15 
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Scheme 3: (a) DCC, HOBt, DIEA, CH2C12; (b) 1.5 equiv 11, NaB(OAc)3H, pH 5, THF, AcOH, 0 °C; (c) 2.2 equiv 
11, NaB(OAc)3H, pH 5, THF, AcOH, 0 °C. (d) 1.3 eq 12, DCC, HOBt, DIEA, CH2C12. 
A convergent strategy was used for the synthesis of neo-C-glycopeptide 4 (Scheme 4). The two subunits 
consist of the dipeptide (8) and a di-glycosylated amino acid (16). Di-glycosylated amino acid (16) was 
obtained through the following steps. Reductive amination of the p-toluenesulfonic acid salt of Gly-OBn (6) 
with the aldehyde (11) gave 14 as the mono-reductive product. This was followed by coupling with acid 12 
using the DCC/HOBt method to obtain 15. The final step consisted of deprotection by hydrogenation with 10% 
Pd/C in 95% EtOH (-COOBn to -COOH) yielding the desired subunit 16. Coupling of 16 with dipeptide 8 gave 
neo-glycopeptide 4 in 70% isolated yield after purification over silica gel.15 
O 
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Scheme 4: (a) DIEA, NaB(OAc)3H, pH 5, THF, AcOH, 0 °C; (b) 12, DCC, HOBt, DIEA, CH2C12; (c) H 2, 10% 
Pd/C, 95% EtOH; (d) 8, DCC, HOBt, D1EA, CH2CI 2. 
To summarize, the synthesis of neo-C-glycopeptides as building blocks required for the synthesis of higher 
neo-C-glycopeptides has been achieved employing (i) stereoselective C-allylation of a galactose derivative, (ii) 
oxidation of the allyl group to a -CHO group, and (iii) reductive amination of the sugar derivative with a 
protected dipeptide having a free amino group on the side chain. A convergent approach to branched side 
chains, in which two galactose units are attached to a glycine derivative in a stepwise procedure (reductive 
amination and amide coupling), followed by coupling to the protected dipeptide (Scheme 4) has also been 
developed. As a continuation, using the deprotected (-COOBn to -COOH) forms of neo-C-glycopeptides (1--4), 
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systematic synthesis of higher neo-C-glycopeptides is under study. 16 Binding studies with various derivatives of 
neo-C-glycopeptides employing cell agglutination assays and surface plasmon resonance technique using plant 
lectin, Maelura Pomifera, (specific for c~-galactose) will be reported in due time. 16 
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